Opendata, web and dolomites

CHAMPION SIGNED

Cartilage Healing Approach Merging Polymer InnOvation with Nature

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CHAMPION project word cloud

Explore the words cloud of the CHAMPION project. It provides you a very rough idea of what is the project "CHAMPION" about.

centres    promise    injuries    complexity    poor    trials    defect    fibrinogen    time    barrier    synchronized    rate    surgery    ultraviolet    inwards    situ    painful    prochondrogenic    annually    implant    osteoarthritis    limited    form    ce    optimal    unlike    focal    preventing    longterm    gelrinc    biologicals    resorbable    body    injury    light    patients    requiring    off    degradation    cartilage    shape    multiple    treatment    acellular    conforming    clinical    outside    articular    implantation    failed    migration    gradually    completing    realized    successful    entrance    ready    treatments    right    glycol    human    stem    outcome    arthroscopic    implants    optimizing    microfracture    commercialization    regulatory    risks    polyethylene    joint    benefit    cells    total    undesired    resorbs    stimulation    designed    limiting    microenvironment    quick    interventions    procedure    channels    therapeutic    shelf    replacement    chondrocytes    cell    marrow    elusive    pursuit    cured    symptomatic    harnesses    defects    mode    re    excellence    liquid    afflicts    million    action    differentiate    bone    replaced    cellular    frequent    gained    knee    alternative    hyaline    denatured    mark    2017    market   

Project "CHAMPION" data sheet

The following table provides information about the project.

Coordinator
REGENTIS BIOMATERIALS LTD 

Organization address
address: HA ILAN STREET 2 NORTHERN INDUSTRIAL ZONE
city: OR AKIVA
postcode: 30600
website: www.regentis.co.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙121˙700 €
 EC max contribution 2˙185˙190 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGENTIS BIOMATERIALS LTD IL (OR AKIVA) coordinator 2˙185˙190.00

Map

 Project objective

Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process. GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials,improving the procedure towards arthroscopic implantation; and creating commercialization channels including centres of excellence in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHAMPION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHAMPION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More